Denovo Biopharma

OverviewSuggest Edit

Denovo Biopharma is a biotech company providing a biomarker solution to personalize drug development. It offers a platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. The technology can be used for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effects. The company aims to enable biotech and pharmaceutical companies to design new clinical trials in targeted patient population to achieve higher efficacy and/or less adverse effects.

Latest Updates

Employees (est.) (Feb 2021)27(+8%)
Cybersecurity ratingDMore

Key People/Management at Denovo Biopharma

Wen Luo

Wen Luo

Chief Executive Officer, Chief Scientific Officer
Xiangming Fang

Xiangming Fang

Chief Operating Officer
Michael Haller

Michael Haller

Chief Business Officer
Xiao-Xiong Lu

Xiao-Xiong Lu

Chief Technical Officer
Carrie Chen

Carrie Chen

Chief Financial Officer
Thomas Heineman

Thomas Heineman

Senior Vice President, Clinical Development
Show more

Denovo Biopharma Financials and Metrics

Summary Metrics

Founding Date


Denovo Biopharma total Funding

$171.6 m

Denovo Biopharma latest funding size

$46 m

Time since last funding

3 months ago

Denovo Biopharma investors

Denovo Biopharma's latest funding round in December 2020 was reported to be $46 m. In total, Denovo Biopharma has raised $171.6 m
Show all financial metrics

Denovo Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Denovo Biopharma Online and Social Media Presence

Embed Graph

Denovo Biopharma Frequently Asked Questions

  • When was Denovo Biopharma founded?

    Denovo Biopharma was founded in 2011.

  • Who are Denovo Biopharma key executives?

    Denovo Biopharma's key executives are Wen Luo, Xiangming Fang and Michael Haller.

  • How many employees does Denovo Biopharma have?

    Denovo Biopharma has 27 employees.

  • Who are Denovo Biopharma competitors?

    Competitors of Denovo Biopharma include Inositec, Naicons and Crescita Therapeutics.